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1. Introduction 
Pancreas transplantation is well recognised and established treatment for selected patients 
with type-1 diabetes. Furthermore, this treatment remains the only therapeutic modality to 
offer excellent and reliable glycemia control, without the administration of insulin in type-1 
diabetics.  
It is well documented that combination of pancreas and kidney transplant (i.e. Simultaneous 
Pancreas and Kidney Transplantation or Pancreas After Kidney Transplantation) gives to 
patients who suffer from type-1 diabetes and End-Stage Renal Failure superior outcomes, 
improved patients’ survival and better quality of life compared to other therapeutic 
modalities. 
In this chapter will be reviewed current status of pancreas transplantation with focus on 
recipient selection, management and outcomes. 
2. Diabetic Nephropathy 
2.1 Definition 
Diabetic nephropathy (DN) has been acknowledged as the most common disorder leading 
to End-Stage Renal Failure (ESRF) in adults (Fig. 1). Renal disease is associated with higher 
morbidity and mortality in diabetics compared to patients who do not suffer from diabetes. 
Approximately 0.5% of the population in developed countries (United States and Europe, 
i.e. Western societies) is thought to have diabetes (ADA, 1999). It is well known that DN is 
the most common diabetic complication. Patients with type-1 diabetes have the highest risk 
of developing nephropathy, but those with type-2 have significant risk, too. This condition 
develops in 50% of type-1 diabetics progressively over a period of 10 to 15 years. In contrast, 
people suffering from type-2 diabetes can undergo a more variable course and 
approximately 30% of them will develop DN at some point. 
2.2 Etiology 
The patho-physiologic mechanisms of diabetic nephropathy are not completely understood 
yet, but they include hyperglycemia (causing hyperfiltration and renal injury), glycosylation of 
circulating and intrarenal proteins, hypertension, and abnormal intrarenal hemodynamics. 
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Fig. 1. Primary Causes of Kidney failure (Collins et al., 2008). 
For DN are typically three major histological changes that seem to have a similar prognostic 
impact. Mesangial expansion is induced by hyperglycaemia, causing matrix production or 
glycosylation of matrix proteins. Another common feature is glomerular sclerosis caused by 
intraglomerular hypertension; induced by renal vasodilatation or from ischemic injury 
induced by the hyaline narrowing of the vessels supplying glomeruli. Glomerular basement 
membran thickening is another common feature, too. 
2.3 Secondary complication of diabetes 
Among patients with DN we see an increased prevalence of other secondary diabetic 
complications. Hypertension significantly increases diabetes-related morbidity and is the 
second most common cause of morbidity in diabetics. It has been documented that 
hypertension increases mortality in diabetics with renal failure by 37 folders (MacLeod & 
McLay, 1998). Hypertension also contributes to the developing of DN, microvascular and 
macrovascular complications.  
Diabetic micro and macroangiopatic complications develop simultaneously and have a 
widespread effect on many organs as well as participating on the development of various 
diseases (diabetic nephropathy, retinopathy, coronary artery disease, peripheral vascular 
disease, cerebrovascular disease, etc). 
Diabetic retinopathy is the leading cause of visual loss in diabetics due to retinal damage. 
This condition affects up to 80% of patients who have suffered from diabetes for more than 
10 years (Kertes & Johnson, 2007). The main mechanism of diabetes induced retinal damage 
is a combination of cytotoxic effect of high blood glucose levels and hypertension. 
Characteristic retinal lesions include the formation of retinal capillary microaneurysms, 
extensive vascular permeability, vascular occlusion, angio proliferation and basement 
membrane thickening (Matthew et al., 1997). Some studies have demonstrated (Wong et al., 
2008) that the prevalence of retinopathy rises with the increasing duration and severity of 
the diabetes. However, good glycaemia control reduces retinopathy development by more 
than 40% (TDCCTG, 1993). 
In some diabetics, mainly in patients with long standing or poorly controlled diabetes, 
symptoms of hypoglycaemia (e.g. palpitation, sweating, tremor, headache, etc.) do not 
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occur. The absence of these symptoms during hypoglycaemia is called hypoglycaemic 
unawareness. Patients suffering from this condition have a lack of warning signals and 
cannot actively correct their hypoglycaemia before plasma glucose falls to extremely low 
levels. The main factor responsible for the development of hypoglycaemic unawareness is 
autonomic diabetic neuropathy and brain desensitization to hypoglycaemia.  
Absence of glucose homeostasis in diabetes also causes pathological damage and functional 
disturbance of the peripheral (motor and sensor) and autonomic nerves. Frequently, patients 
suffer from motor neuropathy: pain, paresthesia and anesthesia. Autonomic neuropathy 
(arrhythmia, postural hypotension, diabetic diarrhoea, gastroparesis, neurogenic bladder, 
impotence, etc) is less common than peripheral neuropathy, but is a more symptomatic and 
has limited therapeutic effect (Watkins & Edmonds, 1997). 
The development of complications is related to the severity and length of diabetes, and its 
management involves glucose control and symptomatic treatment which seems to have a 
positive effect (Ward, 1997). 
2.4 Management  
In recent years, there has been significant progress in the management and treatment of 
diabetics. We have seen not only a reduced morbidity but also increased patients’ survival 
and improved patients’ quality of life. Median patient survival in recent years amongst this 
population has increased from 6 to 15 years (Wiesbauer et al., 2010). 
It is well known that poor diabetic control is responsible for developing various diabetic 
complications; mainly DN. The risk of developing nephropathy is significantly reduced if 
HbA1c stays below 7.5-8.0% (Deferrari et al., 1998; Di Landro et al, 1998). For that reason the 
American Diabetes Association highlights in their “Guidelines for Glycemic Control” to 
target HBA1c level below 7% to achieve a normal or near normal glycemia (ADA, 2005). 
It was documented in two large studies on a cohort of 1349 patients, the DCCT (Diabetes 
Controlled and Complication Trial) and EDIC (Epidemiology of Diabetes Intervention and 
Complications) that tight glycemic control decreases the risk of development of 
microvascular disease (retinopathy, nephropathy, and neuropathy) and even slows down 
established DN (TDCCTRG, 1993), (DCCT, 2003).  
In brittle type-1 diabetes serum glucose levels can rapidly swing between extremely low and 
high levels. This can lead to the development of acute and life threatening conditions: keto-
acidosis, coma or even death. Often patients have absent warning symptoms. In some 
diabetics it is difficult, and even impossible, to achieve a good glycemic control with 
conventional management.  
Nowadays, varieties of insulin preparations are available. The type, the dose and the 
frequency of insulin doses depends on patient’s individual factors. For type-1 diabetics 
“Basal-bolus insulin regiment” (a combination of high frequency boluses of short-acting 
insulin with long-acting insulin) is often used. Some people benefit from “Mixed insulin 
regiment”. This includes a mixture of short and long-acting insulin delivered two to three 
times a day. Regardless of meticulous blood glucose monitoring and accurate insulin 
dosage, some patients may still have problems achieving an appropriate blood glucose level. 
These patients may be considered for an insulin pump. The disadvantage of this method is 
increased frequency of hypo/hyper glycemia episodes and also the fact that it requires a 
cannula implantation (Collins et al., 2007). 
The innovations in insulin formulation and delivery have had a significant impact on the 
management of type-1 diabetes and they have improved glycaemic control. Despite this 
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progress, many patients cannot achieve a good degree of serum glucose control and keep 
suffering from frequent sudden hypoglycaemia episodes. These circumstances have a 
negative impact on patients’ quality of life and can even be life threatening.  
In addition, sufficient management of DN also includes rigorous treatment of hypertension 
in combination with conventional management of renal failure, hyperlipidemia, anaemia, 
etc. 
3. Pancreas transplantation 
The first pancreas transplant was performed at the University of Minnesota, in Minneapolis, 
on 17 December 1966 by the team led by Dr William Kelly and Dr Richard Lillehei (Kelly et 
all., 1967). A pancreas, together with a kidney, was implanted to a 28-year old woman. 
Immediately after the transplantation the patient became euglycemic, but unfortunately she 
died three months later from a pulmonary embolism with functioning grafts. The same team 
in Minneapolis, on 3 June 1969, performed the first successful pancreas transplant and the 
pancreas graft functioned for more than one year (Lillehei & et al., 1970). Early experiences 
with pancreas transplantation were disappointing, as they were associated with a high 
incidence of rejection, infectious complications and early graft failure. Progressively in the 
late 70’s and early 80’s the results of pancreas transplantation improved. First of all, the 
original Lillehei surgical technique was modified and refined. In 1988 Starz published a 
technique of anastomozing graft duodenum to the recipient jejunum for draining a pancreas 
graft exocrine secretion (Fig 2) (Starzl et al., 1988). Subsequently, his technique was adopted 
by other big pancreas transplant institutions; by Dr Hans Sollinger at the University of  
 
 
Fig. 2. The Enteric drainage technique in simultaneous pancreas and kidney transplantation. 
Pancreas graft duodenum is anastomosed side-to-side to the jejunum of a recipient.  
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Wisconsin and Dr Robert Corry at the University of Iowa. Later, all three centres employed 
to their routine practice the technique of draining graft duodenum to the bladder (Fig 3) 
(Sutherland et al., 1988; Sollinger & Belzer, 1988; Corry, 1988). Both techniques, with 
minimal modifications are still used these days. A number of studies compared the 
outcomes between bladder and enteric drained pancreas transplants. Most of them showed 
similar complication rates (Lo et al., 2001; Stratta et al., 2000), graft and patient survival 
(Sugitani et al., 1998).  
 
 
Fig. 3. The Bladder drainage technique in simultaneous pancreas and kidney 
transplantation. Pancreas graft duodenum is anastomosed side-to-side to the bladder of a 
recipient.  
The Enteric Drainage pancreas technique compared (ED) to the Bladder Drainage pancreas 
technique (BD) is a more physiological option because it drains pancreatic enzymes into 
intestinal track. However, this technique is associated with a higher rate of surgical 
complications (anastomotic leak, chemical and infectious peritonitis, ileus, intra-abdominal 
abscess formation, etc.). A typical complication of bladder drainage technique is the 
recurrence of urinary track infections, haematuria, urethral strictures, prostatitis, 
pyeloneophritis, reflux pancreatitis, etc. Additionally to these complications, the urinary 
diversion of exocrine pancreas graft secretion potentiates excessive loss of bicarbonates, 
sodium and fluid. This results in acid-base and electrolytes disturbance (metabolic acidosis) 
and fluid depletion. Metabolic acidosis is even more exacerbated by renal dysfunction. For 
those reasons, serum electrolytes must be closely monitored in patients with bladder 
drained pancreas, patients must be well hydrated and receive bicarbonate supplements. 
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Enteric conversion is a surgical alternative to manage sever complications related to the 
bladder drainage of pancreas graft (Stephanian et al., 1992). The United Network for Organ 
Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) data from 2005 
reports the overall conversion rate from BD to ED of 9% at 1 year and 17% at 3 years after 
transplant (Gruessner & Sutherland, 2005). The major indications for conversion were 
recurrent episodes of haematuria, graft pancreatitis, chronic urinary track infections, 
dehydration and bladder calculi (Jimenez-Romero, et al., 2009). 
In terms of pancreas venous drainage there are two available variations: portal venous and 
systemic venous drainage. Portal drainage is a more physiological alternative, but with 
regards to the complication rate; graft and patient survival there are not any significant 
differences. Some data suggests that portal venous drainage is an important factor to 
determine peripheral insulin sensitivity (Radziuk et al., 1993). In portal venous drainage, 
serum glucose and insulin concentration recover to normal in contrast with systemic venous 
drainage, where plasma insulin levels are increased, as a result of bypassing liver circulation 
(Gu et al., 2002). Hyperinsulinemia contributes to hyperlipidemia, hypercholesterolemia and 
accelerate the development of atherosclerosis.  
A milestone in the history of transplantation occurred in 1976, when Calne published the 
first clinical experiences with Cyclosporin-A. He reported improved graft and patients’ 
survival in a cohort of 34 transplant recipients (32 kidneys, 2 pancreases and 2 livers) who 
received only Cyclosporin-A maintenance immunosuppressive regiment (Lillehei et al., 
1979). A Cyclosporin-A helped to achieve a better control of rejection and minimise steroid 
dependence.  Although, the introduction of new immunosuppressive drugs (tacrolimus,  
 
 
Fig. 4. Pancreas transplant activity rate (incidence per million population) in USA and 13 
European countries considered together (SEC) and individually during the period 2002–06 
(Gonzales-Posada et al. 2010). 
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2002 287.67 366.73 8.07 10.31 5.37 5.19 61.40 82.44 56.99 16.10 4.52 40.96 8.91 7.25 59.22 
2003 290.34 368.82 8.10 10.36 5.38 5.21 61.83 82.54 57.32 16.19 4.55 41.66 8.94 7.31 59.44 
2004 293.03 371.05 8.14 10.40 5.40 5.22 62.25 82.53 57.89 16.26 4.58 42.34 8.98 7.36 59.70 
2005 295.73 373.34 8.21 10.45 5.41 5.24 62.64 82.50 58.46 16.30 4.61 43.04 9.01 7.41 60.06 
2006 298.44 375.29 8.27 10.51 5.43 5.26 63.00 82.44 58.75 16.33 4.64 43.76 9.05 7.46 60.39 
Pancreas Txc 
2002 1460 591 43 64 0 0 59 161 77 17 17 69 8 13 59 
2003 1373 614 37 41 0 0 70 191 77 17 17 74 17 14 59 
2004 1483 657 37 24 0 0 103 187 95 22 10 74 8 11 86 
2005 1444 678 33 24 0 0 92 165 87 21 11 96 7 9 133 
2006 1386 718 39 26 0 0 90 141 90 23 6 94 6 10 193 
Pancreas WLd 
2002 2835 897 38 56 0 0 189 180 245 15 11 47 20 6 90 
2003 2747 877 42 56 0 0 199 145 213 14 11 75 19 5 98 
2004 2388 918 36 53 0 0 178 158 216 34 13 79 14 8 132 
2005 2071 920 38 34 0 0 169 169 197 40 10 87 15 16 145 
2006 1984 1009 32 30 0 0 169 190 222 40 10 73 15 21 207 
DDe                
2002 6190 6422 195 223 73 89 1198 1001 1020 202 62 1409 98 75 777 
2003 6457 6598 187 248 75 85 1119 1110 1042 223 87 1443 114 95 770 
2004 7150 6898 181 220 64 109 1291 1052 1203 228 90 1495 123 91 751 
2005 7593 7159 200 237 63 85 1371 1185 1197 217 76 1546 128 90 764 
2006 8024 7340 201 273 62 109 1442 1227 1231 200 76 1509 137 80 793 
a All 13 countries. 
b Million inhabitants. 
c Tx = transplants. 
d WL = waiting list. 
e DD = deceased donors. 
Table 1. Population, total number of pancreas transplants, pancreas waiting list and DD in 
USA and 13 European countries (Gonzales-Posada et al. 2010). 
MMF, sirolimus, antibody based agents) contributed to further improved graft survival, 
reduction of rejection rate and the overall expansion of transplantation. 
These days, pancreas transplantation has become a worldwide popular therapeutic 
alternative for type-1 diabetics. According to data from the United Network for Organ 
Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR), more than 
30,000 pancreas transplants have been performed worldwide (>22,000 reported from the 
United States and >8,000 from rest of the world) between December 1966 and 31 December 
2008 (UNOS & IPTR, 2008). The majority pancreas transplants have been performed in 
North America and Western Europe (Fig 4), (Tab. 1) (Gonzales-Posada et al. 2010). 
4. Indication of pancreas transplantation 
At the present, Pancreas Transplantation is the only therapeutic modality that can achieve 
full insulin independence and euglycemic state in type-1 diabetic patients. It is well known 
that normoglycemia has a positive impact on preventing secondary diabetic complications. 
Therefore, this modality does not only improve patients’ quality of life but also it has a 
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positive impact on patients’ medical conditions. Nevertheless, this therapeutic alternative is 
recommended only to a selected group of diabetics.  
For a pancreas transplantation should be considered patients with brittle type-1 diabetes 
who suffer from secondary diabetic complications (diabetic nephropathy, diabetic 
retinopathy, diabetic neuropathy, diabetic gastro-enetopathy, etc); frequent hypoglycaemic 
episodes or hypoglycaemic unawareness and failure to achieve eu-glycemia even on 
intensive insulin treatment (insulin pump, etc.).  
A detailed assessment of potential candidates for pancreas transplantation is mandatory 
because many of these patients have pre-existing cardiac diseases or other medical problems 
related to diabetes, and these may significantly increase per-operative morbidity, mortality 
and early graft failure. 
4.1 Diabetes assessment 
The first part of the evaluation is to determine the type of diabetes. It is generally accepted 
that pancreas transplantation should be reserved for type-1 diabetics. However, there are 
published data repording successes of pancreas transplantation also in type-2 diabetic 
patients. Nevertheless, a more strict patients’ selection is required (Orlando et al., 2010). For 
diagnosis type-1 diabetes it is satisfactory to detect an absence or very low levels of C-
peptide together with raised HbA1c (>7.5%). However, the patient’s considered for pancreas 
transplantation cannot exceed insulin requirements beyond 1.5mg/kg/day; as this is the 
marker of peripheral insulin resistance. These patients do not achieve full insulin 
independence even with successful pancreas transplantation. Patients who are failing to 
achieve a reasonable serum-glucose control with conventional insulin treatment should be 
also considered for pancreas transplantation. Usually, they suffer from frequent hypo and 
hyper-glycemic episodes. Sever hypoglycaemia is the most common casualty in diabetics on 
insulin treatment. These complications are potentially life-threatening, associated with high 
morbidity and mortality rate.  
4.2 Cardiac evaluation  
Diabetes doubles the risk of developing cardio-vascular disease; coronary-artery disease, 
cerebro-vascular disease and peripheral vascular disease (Grundy et al., 1999). Over 50% of 
diabetics have some degree of coronary artery disease.  Also, it is well known that diabetics 
suffer from accelerated atherosclerosis and a high incident of silent ischemia and cardio-
myopathy compared to the non-diabetic population. Furthermore, cardio-vascular disease is 
the leading cause of death in the general population (35%) but diabetic patients are two 
times (67%) more likely to die due to this cause (Watkins, 2003). 
The key purpose of the pre-transplant cardiac assessment is to identify risk factors 
(reversible ischemia, impaired left ventricular function, coronary artery disease, etc.) that 
may increase per-operative morbidity and mortality; and minimize them with the 
appropriate management and treatment. For cardiac evaluation standard echocardiography, 
Dobutamine stress echocardiography (DSE), exercise tolerance testing, nuclear (thalium) 
myocardial perfusion scan and formal coronary angiogram are routinely used. Because each 
of these tests has some limitations, there is not a consensus yet regarding which method has 
the highest predicting value. 
Dobutamine stress echocardiography (DSE) is a non-invasive imaging modality which 
combines two-dimensional echocardiography with cardiovascular stress induced by 
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dobutamine infusion. This test is sensitive to detect coronary artery disease in 
asymptomatic, high risk (diabetic, patients with peripheral vascular disease, etc.) patients.  
The nuclear myocardial perfusion study (MPI) is a sensitive, non-invasive test for the 
assessment of myocardial perfusion, ejection fraction, wall motion and wall thickness. Stress 
radionuclide myocardial perfusion imaging, on the other hand, displays the downstream 
functional consequences of epicardial coronary artery disease in the myocardium. It also 
may visualize the regional effects of micro vascular endothelial dysfunction and impairment 
of regional coronary flow reserve. 
DSE and MPI methods are generally accepted as standard and non-invasive screening 
studies useful to identify patients (diabetics with ESRF) with significantly increased risk of 
myocardial infarction or cardiac death (Rabbat et al., 2003; Cai et al., 2010). Nevertheless, 
they have low sensitivity and specificity to define coronary artery disease in patients with 
ESRD (Letine et al., 2010). 
On the other hand, the coronary-angiogram (CA) offers high sensitivity to detect coronary-
artery disease but it is limited in regards to predicting survival. This is mainly because 
myocardial infarction is more likely to be caused by plague instability rather than 
angiographic stenosis. Additionally, the contrast used for this test is nephro-toxic and it can 
have a catastrophic impact on impaired kidney function (Letine et al., 2010). 
There is only one published study which directly compares doputamine stress 
echocardiography to coronary angiogram in renal transplant candidates (Herzog et al., 
1999). Fifty potential transplant candidates underwent DSE followed by CA.  Twenty of fifty 
DSE were positive for inducible ischemia. Sensitivity and specificity of DSE were 52% and 
74%, respectively, for stenosis ≥50%; 75% and 71% for stenosis greater than 70%; 75% and 
57% for stenosis greater than 75%. At the end the authors concluded that DSE is a good 
screening method, in spite of low sensitivity to detect coronary artery disease. For that 
reason, CA is reserved for high risk groups of patient with a previous history of cardiac 
problems (cardiac event, ishemic heart desease etc) or for patients with positive stress 
echocardiography or MPI scan. 
4.3 Dietitian management 
4.3.1 Pre-transplant assessment 
A well balanced nutrition in transplant recipients plays a vital role in a pre and pos-
transplant period to ensure the best possible outcomes. The role of a dietician is to evaluate 
the patient’s nutrition status and design a nutrition plan for a pos-transplant period. For that 
reason it is important we ensure pre-operatively the following parameters:  
a. Good glucose control: It is well documented (Kuo et al., 2010) that diabetes mellitus is a 
major predictor of cardiovascular morbidity and mortality in kidney transplant 
recipients. A recent study (Sato et al., 2010) analysed the outcomes of patients 
undergoing cardiac surgery and revealed that increased of HbA1c levels (>6.5%) 
predicts insulin sensitivity and increases the incidence of major complications. In 
addition, a well controlled diabetes improves gastroparesis and delays gastric empting 
(Reddy, 2010) as well as preventing other gastro intestinal symptoms including nausea, 
vomiting, bloating, early satiety and abdominal pain (Kashyap & Farrugia, 2010). 
b. Weight maintenance:  A Body Mass Index (BMI) ≥25kgs/m2 is a strong predictive factor 
with significantly negative impact on long term renal graft outcomes (Cheung et al., 
2010). So, in these patients weight loss is strongly recommended.   
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c. Balanced nutrition status: Prior to transplantation it is also crucial to optimize good 
nutrition status in patients with low BMI. According to some data (Meier-Kriesche et al, 
2002) poor nutrition is associated with significantly worse patient and graft survival. 
d. Adequate electrolyte balance: Patients with chronic renal failure may be on a low 
potassium, phosphate and low salt diets and fluid restrictions.  Raised levels of 
potassium and phosphate are associated with increased mortality in these patients 
(Noori et al 2010; Ganesh et al., 2001). 
4.3.2 Immediate pos-transplant management  
The transplant recipient must receive adequate nutrition support (25-30 kcal/kg ideal body 
weight per day) during the first seven pos-operative days to avoid starvation and to 
enhance postoperative recovery (Braga et al., 2009). We should aim to identify the patient’s 
post-transplant nutrition requirements prior to a surgery and in advance to design an 
individual sufficient nutrition plan. 
The European Society for Clinical Nutrition and Metabolism (ESPEN) developed guidelines 
on enteral nutrition management after surgery (Weiman et al., 2006). These guidelines 
suggest that oral diet and supplements should be initiated early after surgery, where 
possible. Furthermore, enteral nutrition should be considered in patients with obvious 
under-nutrition and those whose oral intake will be inadequate (<60% of requirements) for 
10 days after surgery. These patients should ideally have a naso-jejunal tube placed during 
surgery and feeding commenced on the first pos-operative day. According to these 
guidelines, parenteral nutrition is reserved for those patients who are unable to tolerate 
enteral feeding; due to complication including interstinal obstruction, ileus and sever shock 
(Braga et al., 2009). 
4.3.3 Pos-transplant surveillance  
In the long term, it is important to maintain a healthy weight and maintain good nutrition 
status. A team from the Netherlands (Hoogeveen et al., 2011) reports that 1-year post-
transplant BMI is more strongly related to death and graft failure than pre-transplant BMI. 
According these data, patients who reached pos-transplant BMI>30 kg/m2 have a 20-40% 
higher risk of death and graft failure compared to patients with lower BMI. 
4.4 Other tests 
A routine part of the pre-transplant assessment includes blood tests: 
a. Haematology Blood Tests: Blood group identifying, antibody screen, full blood count, 
Thrombophilia screen, APTT, PT, and INR. 
b. Biochemistry Test: Urea & electrolytes, creatinine, uric acid, calcium, phosphate, 24-hour 
urine collection  (tested for protein/micro albuminuria and creatinine clearance), eGFR 
(radioisotope glomerular filtration rate if needed), liver function tests, amylase, thyroid 
function, fasting blood glucose, fasting and stimulated C-peptide levels if needed, 
fasting blood lipids. 
Additional studies may include oral or intravenous glucose challenge, anti-insulin and 
islet cell antibodies, proinsulin level and lipoprotein. 
c. Viral screen: Hepatitis B and C, HIV, HTLV, BK virus, Polioma virus, Syphilis, Rubella, 
Epstein Barr Virus, Toxoplasma, Varicella-Zoster, Herpes , simplex, Cytomegalovirus. 
d. Immunology Blood Tests: HLA typing and antibody screening. 
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5. Contraindications  
Overall, contraindications to pancreas transplantation are the same as for kidney 
transplantation, and they are often determined by patient co-morbidity.  
5.1 Absolute contraindications 
a. Insufficient cardiovascular reserve: 
 Ejection fraction below 50% 
 Myocardial infarction within 6 months 
 Non-correctable coronary artery disease or refractory congestive heart failure 
b.    Non curable malignancy (excluding localised skin malignancy) 
c.    Active sepsis 
d.    Active peptic ulcer 
e.    Major psychiatric history likely to result in non-compliance 
f.     Inability to withstand surgery and immunosuppression 
(UKT, 2003) 
Some contraindications are relative and must be individually assessed and discussed with 
the responsible specialist on multidisciplinary bases and with the patient, too. 
5.2 Relative contraindications  
a. Cerebrovascular accident with long term impairment.  
b. HIV (subject to discussion). 
c. Chronic liver disease: Candidates with Hepatitis B/C need recent viral screen, LFT and 
assessment by hepatologist prior activating on a WL. The aim is to exclude active viral 
disease as well as advanced irreversible liver disease. 
d. Body Mass Index greater than 30. 
e. Malignancy: In patients with a history of cancer a cancer free interval from three to five 
years according the type of cancer, stage and cancer therapy are required. This issue 
must be discussed in detail with an oncologist. A valuable source of information is 
“Israel Penn International Transplant Tumor Registry” (www.ipittr.org). 
f. Type-2 diabetes was originally an absolute contraindication to pancreas transplantation. 
However, a recently published review reports that selected group type-2 diabetics 
benefit from whole organ pancreas transplantation, too. Transplant outcomes (after 
SPK) are comparable between type 1 and 2 diabetics. But a strict patient selection is 
required; BMI less than 30 kg/m2, insulin requirements <1.0 units/kg/day, C-peptide 
level less than 10 ng/ml, etc. (Orlando et al., 2010). 
g. Extensive aorta/iliac and/or peripheral vascular disease. 
h. Continued abuse of alcohol, smoking or other drugs. 
(UKT, 2003) 
6. Transplant alternatives for diabetic patients  
For diabetic patients with ESRF three transplant alternatives are currently available: kidney 
transplantation (including cadaver and living donor kidney transplantation); Simultaneous 
Pancreas-Kidney Transplantation (SPK) and Pancreas After Kidney Transplantation (PAK). 
Each of them has some recognised advantages and disadvantages (Tab. 2).  
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 Advantages Disadvantages 
CKT Provides better survival than dialysis 
options 
Inferior to other transplant options 
with respect to kidney graft survival 
and patient survival 
LRD Minimizes waiting time, time spent 
on dialysis 
Very low early morbidity and 
mortality 
Absence to normalize of blood 
glucose 
Inferior patient survival over time 
when compared with SPK recipients 
with functioning grafts 
SPK Glycemic control, with recent median 
pancreas graft survival of >10  years 
High-quality, deceased donor kidney 
graft 
Higher morbidity and mortality due 
to larger operation 
If pancreas fails within the first year, 
outcomes are worse than LRD 
PAK Glycemic control 
If living donor kidney transplant, 
comparable/better patient and 
kidney graft survival than LRD 
 
Two separate surgical procedures, 
increased mortality early 
postoperatively following pancreas 
transplant 
Historically inferior pancreas graft 
survival (35% at 10   years) than SPK 
Table 2. Summary of advantages and disadvantages of transplant options for diabetic 
kidney disease (Wiseman, 2010). 
6.1 Kidney transplantation  
Kidney transplantation is a widely used and well accepted transplant option for patient 
with ESRF secondary to DN. It is indisputable that this alternative gives survival advantages 
to these patients over chronic dialysis. The estimated survival of a diabetic on dialysis is 
only 30-40% at five years, while kidney transplantation increases their 5 year survival to up 
to 70% for Cadaver Kidney Transplantation (CKT), and to up to 80% for Living Donor 
Kidney Transplantation (LRD) (Reddy et al., 2003; USRDS 1998; Cecka et al. 1997). As we 
know, LRD is associated with better outcomes due to a superior quality of kidney graft and 
reduced cold ischemia time. This type of transplantation has relatively low risk of post-
transplant complications (10-12%) and compared to pancreas transplantation it is less 
traumatic, too. For that reason, a greater population of diabetic patients with ESRF is eligible 
for renal transplantation rather pancreas transplantation. A successfully treated ESRF with 
renal transplantation does not only improve overall patients’ medical conditions (anaemia, 
hypertension, etc) but in many cases it also stabilises brittle diabetes.  
6.2 Simultaneous pancreas and kidney transplantation  
During recent years, Simultaneous Pancreas and Kidney Transplantation (SPK) has become 
the most popular transplant alternative and golden standard for type-1 diabetic with ESRF. 
Additionally to renal transplantation in these patients pancreas transplantation helps to 
achieve euglycemia, insulin independence and enhances patients’ quality of life 
(Sureshkumar et al., 2006). Also, the tight glycaemic control prevents the recurrence of 
diabetic nephropathy and improves secondary diabetic complications; mainly diabetic 
retinopathy, cardiovascular disease, diabetic neuropathy, etc.  
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Overall, it has been proven that SPK gives some survival benefits to these patients. In one of 
the largest studies (Ojo et al., 2001) SPK was associated with a 10-year patient survival of 
67% compared to 46% in a CKT recipient group. However, in comparison with the LRD 
benefit of SPK, in terms of patient and graft survival, it does diminish. Wisconsin 
experiences (Tab. 3) (Rayhill et al., 2000) have shown that patient and renal graft survival 
was not different between the LRD and the SPK groups, but it was significantly lower in the 
CKT group (Fig 5,6) (Young et al., 2009). 
The main advantage of LRD is the low immunological risk and good quality kidney graft 
that participates on excellent kidney function and prolongs graft survival. However, only an 
additional pancreas transplant gives a protective role to prevent the recurrence of DN, 
maintain a good kidney function, improve the quality of life and eliminate secondary 
diabetic complications. On the other hand, we cannot forget that SPK is associated with a 
double level of morbidity (20-40%) and mortality (2-5%) compared to kidney transplantion. 
For that reason, younger patients with better medical conditions (Rayhill et al., 2000) should 
be considered for SPK. 
 
 1y patient survival 5-y patient survival 
LRDi 100% 94% 
LRDh 99% 85% 
SPK 96% 88% 
CKT 94% 72% 
 
 1y graft survival 5-y graft survival 
LRDi 96% 85% 
LRDh 94% 72% 
SPK 87% 78% 
CKT 86% 64% 
LRDi – HLA-identical living related donor, LRDh – haplotype-identical living related donor 
Table 3. The 1-year and 5-year pos-transplant outcomes (Rayhill et al., 2000). 
 
 
(LDKT - living  donor  kidney  transplant;  SPKT - simultaneous pancreas  kidney  transplant;  
DDKT - deceased  donor  kidney transplant). 
Fig. 5. Unadjusted kidney graft survival by transplant type (Young et al., 2009). 
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(LDKT - living donor kidney transplant; SPKT - simultaneous pancreas kidney transplant;  
DDKT - deceased donor kidney transplant). 
Fig. 6. Unadjusted patient survival by transplant type (Young et al., 2009). 
6.3 Pancreas after kidney transplantation 
Historically, Pancreas After Kidney Transplantation (PAK) was not a very popular pancreas 
transplant alternative due to the inferior pancreas graft survival compared to SPK. The impact 
of pancreas graft on patients with kidney graft from two different donors was associated with 
high immunological graft failure. However, the development of new immunosuppressive 
regiments based on depleting antibody induction and Tacrolimus and MMF maintenance 
reduced the risk of immunological graft loss and improved graft survival outcomes. For those 
reasons, this alternative has become more popular (Larson et al., 2004). 
Diabetic patients who have undergone kidney transplant or who underwent SPK and have 
lost pancreas graft might be today considered for PAK. With increased frequency, this two-
stage procedure involves a living donor kidney transplantation followed by a cadaver 
pancreas transplant (PALK). This alternative has the advantage of a short waiting time and 
of a superior quality kidney graft (Kleinclauss et al., 2009). The second great advantage of 
PAK is performing major pancreas transplant surgery on a non-uremic patient. This 
minimizes the risk of per-operative morbidity and mortality related to renal failure.  
Pominipanin analysed data of the Organ Procurement Transplant Network/United 
Network of Organ Sharing (OPTN/UNOS) database and compared outcomes of SPK with 
CKT and PALK. He reports that renal graft outcomes were superior in PALK compared to 
SPK. The 1-year pancreas graft survival was marginally higher for the SPK cohort (86%) vs. 
80% for PALK. The overall patient survival was better in PALK compared to SPK (Fig 7 a,b). 
Even this study showed that PAK is an alternative with competitive results to SPK. 
6.4 Simultaneous cadaver pancreas and living donor kidney transplantation 
At present, SPK and PAK are the most common options for uremic type-1 diabetics. SPK is a 
one-stage procedure and this is its main advantage over PAK. On the other hand, PAK has 
the advantage of involving living donor with superior quality of kidney graft function and 
subsequently of performing pancreas transplantation on a non-uremic patient. Simultaneous 
Cadaver Pancreas and Living Donor Kidney Transplantation (SPLK) is an innovative 
approach that merges some benefits of both alternatives; superior quality of living donor 
kidney and s single procedure with shorter waiting time for cadaver pancreas graft. 
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a/ Overall kidney graft survival (%) 
b/ Death censored kidney graft Survival (%) 
PALK - pancreas after living kidney transplant,  
SPKT - simultaneous pancreas kidney transplant,  
LDKT - living donor kidney transplant. 
Fig. 7. Kidney graft survival (Poommipanit et al., 2010). 
Despite increased immunological risk, SPLK showed comparable results with SPK and PAK 
(Boggi et al., 2004). In a study from Maryland (Farney et al., 2000), it was reported that 1-
year pancreas graft survival in the SPLK group was not significantly higher than in SPK and 
PAK (88% vs. 84% vs. 71%) Fig. 8,9,10 (Farney et al., 2000). The 1-year patient survivals were 
95% (SPLK), 94% (SPK) and 100% (PAK). The SPLK group showed lower incidence of delay 
graft function and better kidney function.  
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One-year pancreas graft survival rates were 88%, 84%, and 71%, respectively, for simultaneous cadaver-
donor pancreas and living-donor kidney transplantation (SPLK), simultaneous cadaver kidney and 
pancreas transplantation (SPK)  and living-donor kidney transplantation alone  followed by a solitary  
cadaver-donor pancreas transplant (PAK)  
Fig. 8. Pancreas  graft survival rates (Farney et al., 2000). 
 
 
One-year patient survival rates were 95% and 94% for simultaneous cadaver-donor pancreas and living-
donor kidney transplant (SPLK) and simultaneous cadaver kidney and pancreas transplant (SPK) 
recipients. The patient survival rate was 100% in living-donor kidney transplantation alone followed by 
a solitary cadaver-donor pancreas transplant (PAK) recipients (not shown). 
Fig. 9. Patient survival rates (Farney et al., 2000).  
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One-year kidney graft survival rates were 95% and 89% for simultaneous cadaver-donor pancreas and 
living-donor kidney transplant (SPLK) and simultaneous cadaver kidney and pancreas transplant (SPK) 
recipients. The only SPLK loss was death with function. No living-donor kidney transplantation alone 
followed by a solitary cadaver-donor pancreas transplant (PAK) kidney grafts were lost (not shown). 
Fig. 10. Kidney graft survival rates (Farney et al., 2000).  
7. Surgical complications  
Despite worldwide growing experience with pancreas transplantation, this procedure is still 
associated with high incidence of pos-transplant complications; and compared with other 
solid organ transplants; it has the highest incidence of serious intrabdominal complications 
and reoperations. We know that up to 50% of pancreas recipients develop pos-transplant 
complication and around 32% of patients require further surgery to deal with these 
problems (Troppmann et al., 1998). According the United Network for Organ Sharing 
report, from 11% to 21% of all pancreas grafts are lost because of surgical complication 
(Gruessner & Sutherland, 2005).  
There are recognised several factors that participate in development of postransplan 
complications. Diabetes was found to be the strongest independent risk factor. It is well 
documented that diabetics have significantly higher complication rate compared with non-
diabetic population. Also, these patients receive strong immunosuppressive regiment, 
compared to other solid organ recipients. This makes patients more immunocompromised 
and vulnerable to infection. Open bowel or bladder, during pancreas implantation is other 
possible source of abdominal contamination and infection. Furthermore, SPK recipients are 
compromised by uraemia and PAK recipients are chronically immunosuppressed at the 
time of transplant. Additional risk factors include: older donors and recipients, long cold 
ischemia time and high BMI (UNOS & IPTR, 2008). 
The most common surgical complication after pancreas transplantation is abdominal 
infection and graft pancreatitis (38%), followed by pancreas graft thrombosis (27%) and 
anastomotic leak (9%) (Troppmann et al., 1998). 
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7.1 Thrombosis  
Vascular thrombosis is the second leading cause of pancreas graft failure after rejection. 
Incidence is reported between 2-20% and it can be either arterial or venous (Gruessner & 
Sutherland, 2000). 
It is well known that pancreas is more susceptible to thrombosis than other organs. Pancreas 
has naturally low microvascular flow. Removing the spleen from pancreatic graft as a part 
of the pancreas bench-work, venous flow does reduce even more. The pancreas also requires 
vascular reconstruction because blood supply to the pancreas is divided during 
explantation. The donor iliac artery extension ”Y” graft is joined to the superior mesenteric 
artery and the splenic artery to create a single arterial conduit (Fig. 11). The venous 
extension graft is an additional risk factor causing venous thrombosis. Furthermore, hyper-
coagulable status in renal failure patients and endothelial damage are recognised as other 
negative factors in developing venous thrombosis (Muthusamy et al., 2010). 
 
B
A
C
 
An end-to-end anastomosis between limb of internal iliac artery of the “Y” graft and stump of the 
splenic artery of the pancreas graft; and limb of external iliac artery and stump of the superior 
mesenteric artery. 
A - “Y“graft,  B- superior mesenteric artery, C – splenic artery 
Fig. 11. Vascular reconstruction  
If venous thrombosis occurs, often a patient develops abdominal pain due to organ 
swelling with an acute drop of haemoglobin levels. Raising levels of serum glucose are 
usually late sings of thrombosis. Arterial thrombosis is much less common with a less 
dramatic clinical picture. In the majority of cases, the pancreas graft is non-salvageable 
and requires urgent graftectomy. Some data report that in an early stage urgent 
radiological intervention with thrombectomy or thrombolysis can salvage a pancreas 
allograft (Stockland et al., 2009) (Fig. 12). 
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Fig. 12a 
www.intechopen.com
 Understanding the Complexities of Kidney Transplantation 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12 b 
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Fig. 12 c 
a/ Thrombus in the portal vein of pancreas graft (black arrow points on filling defect, thrombus, in 
portal vein). A thrombectomy catheter is in the graft’s portal vein via right external iliac vein by 
cannulation right femoral vein.  
b/ Status after thrombectomy. Improvement in venous flow and full patency of portal vein without a 
thrombus. 
c/ Normal angiogram of pancreas graft. 
Fig. 12. Conventional angiography of pancreas graft.  
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A key part of the post-operative thrombosis management is prevention, close monitoring, 
early diagnosis and early intervention, but mainly meticulous vascular reconstruction, 
bench-work and refine implantation technique. Patients after transplantation receive a high 
dose of fractionated/continued infusion heparin to develop hypo-coagulable status to 
reduce clot formation. Sensitive markers for careful coagulation monitoring are APTT ratio 
(INR) and Thromboelastogram (TEG) (Burke et al., 2004). Several diagnostic methods are 
recommended for graft monitoring and diagnosis vascular complications: duplex 
ultrasound, CT-angiography or MR-angiography and formal angiography. 
7.2 Bleeding 
This vascular complication does mainly occur in combination with intra-abdominal 
infection or during sever hypo-coagulable status secondary to heparin treatment. Heparin 
induced bleeding usually has a slow progress and it is often managed conservatively; with 
antibiotics and blood transfusions. Bleeding secondary to infection is a serious event and it 
can be life-threatening. Clinical presentation is rapid, sudden hypotension, significant fall of 
haemoglobin levels and pulsative intra-abdominal mass. In that case urgent laparotomy is 
vital to control bleeding and abdominal sepsis. At presence of advanced abdominal sepsis or 
infection involving pancreas graft it is recommended to perform graftectomy to prevent 
fatal bleeding. 
7.3 Pancreatitis 
Graft pancreatitis usually occurs instantly after transplant as a result of excessive handling 
of an organ during retrieval, storage, bench-work and transplantation, as well as a 
consequence of ischemic-reperfusion injury. Most episodes of pancreatitis resolve 
uneventfully, however some may lead to secondary complications (fistula, pseudocyst, etc.). 
Also, Octreotide (synthetic somatostatin analog that inhibits exocrine pancreatic secretion) 
has been used to prevent and treat  some pos-transplant complications (i.e. graft 
pancreatitis, pancreatic fistula). But data from published studies are controversial with no 
statistical difference in complication rate between recipients who received octreotide and 
patient treated by placebo (Stratta et al., 1993). 
7.4 Miscellaneous 
Other common early surgical complications involve anastomotic leak, pancreatic fistula, 
intra-abdominal sepsis, ileus, wound infection, etc. They may cause graft lost and recipients’ 
mortality so it is important to actively search for them, to detect them early and to treat 
them. 
8. Immunosuppression  
The key role of immunosuppression in transplantation is to minimize graft lost due to 
rejection. Despite this major benefit, all immunosuppressive medication has some side 
effects. For that reason, a good immunosuppressive regiment should balance both aspects to 
deliver the best possible outcomes. The pancreas is a more immunogenic organ than the 
kidney, and precisely for that reason the majority of immunosuppressive regiments for 
pancreas transplantation are  mainly based on quadruple drug therapy; including antibody 
agents for induction in combination with calcineurin inhibitors (CNI) and mycophenolate 
mofetil (MMF) or sirolimus and steroids ( Singh & Stratta, 2008).  
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Initially, the IL-2 receptor antagonists (basiliximab, daclizumab) have been used as 
induction agents in pancreas transplantation for long period. In the PIVOT Study 
daclizumab induction was compared to no antibody induction in pancreas transplantation. 
The results showed that daclizumab significantly reduced the incidence of acute rejection. 
The 1-year rejection free interval in the daclizumab group was 68% compared to 51% in the 
non antibody induction group (Stratta et al., 2003). T-cells depleting antibody agents, such 
as antithymocyte globulin (ATG) and alemtuzumab (Campath), have gained great 
popularity these days. According to the United Network of Organ Sharing data, this type of 
induction significantly decreases incidence of immunologically related pancreas graft failure 
(Gruessner & Sutherland, 2003). 
According to a review published in 1999 (Stratta, 1999), a combination of MMF and 
tacrolimus in primary immunosuppressive regiment resulted in an improved 2-years 
patient, kidney and pancreas survivals; 97.7%, 93.3% and 90%, respectively. 
Lymphocyte-depleting antibody agents in combination with tacrolimus, and MMF or 
sirolimus, are effective in preventing acute rejection and allow corticosteroids elimination or 
even full avoidance (Heilman et al., 2010). The principle of the steroid sparing regiment is to 
avoid steroids related side effects (increased risk of hypertension, glucose intolerance, 
cholesterol, infection, cardiovascular events, anaemia, osteoporosis, etc.) in pancreas 
transplant recipients. There is strong evidence that steroid sparing/avoidance regiments are 
safe and effective with a positive impact on patient and graft survival. Also, we have seen 
significantly improved the short-term outcomes whereas the long-term outcomes are still 
insufficient (Mineo et al., 2009). 
9. Monitoring pancreas function 
The development of surgical techniques and immunosuppressive drugs has significantly 
improved short-term outcomes of pancreas transplantation (Fig. 13). So these days the main 
target is to improve long-term results and minimize late graft dysfunction. 
 
 
Fig. 13. Pancreas graft survival by era for all transplants, 1987–2007: UNOS registry analysis. 
B: Pancreas graft survival by era for transplants surviving more than 1 year, 1987–2007: 
UNOS registry analysis (UNOS, 2010). 
Immunological graft loss still remains the main cause of graft failure; its rate in 1-year is 
significantly lower in SPK groups (2%) compared to solitary pancreas transplants (6% for 
PAK and PTA) (Fig 14) (Gruessner et al., 2008).   
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Fig. 14. Pancreas Immunological loss (Waiki et al., 2010).  
The incidence of acute rejection is at its highest early after the transplantation. Induction 
regiments based on antibody depleting agents (i.e. ATG, Campath) delay the repopulation 
of lymphocytes; so the peak of rejection rate is around six to nine months after 
transplantation instead of three months as we see in regiments based on IL-2 receptor 
antagonists induction.  A clinical picture of acute rejection is non-characteristic (fever, 
abdominal pain, ileus, tenderness, diarrhea, haematuria in bladder drained pancreas) or in 
the majority of cases absent.  
Close monitoring of the pancreatic graft is a crucial part of pos-transplant surveillance. 
Unfortunately, there are not any biomarkers that can sensitively predict rejection yet. For 
that reason routinely are monitored the levels of fasting blood glucose, fasting C-peptide, 
HbA1c, serum amylase, serum lipase, oGTT and CRP; but with limited sensitivity and 
specificity. In SPK patients we do monitor serum creatinine as an indirect marker, too. Also, 
we know that islet function is resistant to pancreas damage so serum glucose elevation is a 
late manifestation of pancreas graft dysfunction and predicts poor prognosis; i.e. acute or 
chronic rejection, pancreatitis, thrombosis, etc. 
The bladder-drained pancreas technique gives easy and convenient access to monitor 
pancreas graft function by measuring urine amylase. A low amylase level is a marker of 
graft dysfunction (rejection, pancreatitis, etc). Also, cystoscopy enables to perform repeated 
pancreas graft biopsies with a relatively low risk of complication rate.  
The only objective way to diagnose rejection is a histological evaluation of the pancreas graft. 
Precise diagnoses help to tailor management and subsequently improve graft function. 
Despite a higher incidence of biopsy related complications pancreas graft biopsy is now 
widely employed (Gaber, 2007). SPK cases have a high incidence of synchronous pancreas and 
kidney rejection rate, around 62.5%. Kidney graft biopsy has lower risks of complications 
compared to pancreas biopsy. Also for that reason, kidney biopsy is routinely employed to 
diagnose pancreas graft rejection. On the other hand, there is a 25% occurrence of kidney only 
rejection; that usually correlates with elevation of serum creatinine. In 12.5% cases rejection 
involves only pancreas without involvement of renal graft (Kitada et al., 2009). 
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A successful Banff scheme of grading rejection in kidney (Solez et al., 2007) and liver (ICD, 
1997) transplantation was subsequently applied in pancreas transplantation, too. On the 9th 
Banff conference on Allograft Pathology in 2007 (La Coruña, Spain) a final version (Tab. 4,5) 
of Banff Schema for Grading Pancreas Allograft Rejection was agreed (Drachenberg et al., 
2008). 
10. Benefits of pancreas transplantation 
The main purpose of pancreas transplantation is to achieve eu-glycemia, insulin 
independence and improve the quality of life in diabetics. A number of studies examined 
the impact of successful pancreas transplantation also on secondary diabetic complications 
(nephropathy, retinopathy, neuropathy, etc).   
Nephropathy: Diabetic nephropathy has a high recurrence rate, effects almost all kidney 
grafts and can lead to graft failure. Development of histological sings of diabetic 
nephropathy is seen within two years after transplantation (Bohman et al., 1984). It has been 
well documented that functioning pancreatic grafts have a protective role on kidney graft 
function. Achieving permanent normo-glycemia not only prevents the development of DN 
but it can also reverse histological lesions characteristic for DN (Fioretto et al., 1998).  
Retinopathy: There is good evidence that pancreas transplantation and subsequent 
normoglycemia stabilizes and even improves retinopathy. However, patients with a high 
grade of retinal damage before a transplant may get a progression of retinopathy 
(Königsrainer et al., 1991). 
 
1. Normal. Absent inflammation or inactive septal, mononuclear inflammation not 
involving ducts, veins, arteries or acini. There is no 
graft sclerosis. The fibrous component is limited to normal septa and its amount is 
proportional to the size of the enclosed structures 
(ducts and vessels). The acinar parenchyma shows no signs of atrophy or injury. 
2. Indeterminate. Septal inflammation that appears active but the overall features do not 
fulfill the criteria for mild cell-mediated acute 
rejection. 
3. Cell-mediated rejection 
Acute cell-mediated rejection 
- Grade I/Mild acute cell-mediated rejection 
Active septal inflammation (activated, blastic lymphocytes, ± eosinophils) involving 
septal structures: venulitis (sub-endothelial 
accumulation of inflammatory cells and endothelial damage in septal veins, ductitis 
(epithelial inflammation and damage of ducts). 
Neural/peri-neural inflammation. 
and/or 
Focal acinar inflammation. No more than two inflammatory fociˆper lobule with absent 
or minimal acinar cell injury. 
- Grade II/Moderate acute cell-mediated rejection 
Multi-focal (but not confluent or diffuse) acinar inflammation (≥3 fociˆper lobule) with 
spotty (individual) acinar cell injury and drop-out. 
and/or 
Minimal intimal arteritis 
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- Grade III/Severe acute cell-mediated rejection 
Diffuse, (widespread, extensive) acinar inflammation with focal or diffuse multi-cellular 
/confluent acinar cell necrosis. 
and/or 
Moderate- or severe-intimal arteritis 
and/or 
Transmural inflammation-Necrotizing arteritis 
Chronic active cell-mediated rejection. Chronic allograft arteriopathy (arterial intimal 
fibrosis with mononuclear cell infiltration in fibrosis, 
formation of neo-intima) 
4. Antibody-mediated rejection = C4d positivityºº + confirmed donor specific antibodies 
+ graft dysfunction 
Hyperacute rejection. Immediate graft necrosis (≤1 h) due to preformed antibodies in 
recipient’s blood 
Accelerated antibody-mediated rejection. Severe, fulminant form of antibody-mediated 
rejection with morphological similarities to 
hyperacute rejection but occurring later (within hours or days of transplantation). 
Acute antibody-mediated rejection. Specify percentage of biopsy surface (focal or 
diffuse). Associated histological findings: ranging 
from none to neutrophilic or mononuclear cell margination (capillaritis), thrombosis, 
vasculitis, parenchymal necrosis. 
Chronic active antibody-mediated rejection. Features of categories 4 and 5. 
5. Chronic allograft rejection/graft sclerosis 
- Stage I (mild graft sclerosis) 
Expansion of fibrous septa; the fibrosis occupies less than 30% of the core surface but the 
acinar lobules have eroded, irregular 
contours. The central lobular areas are normal. 
- Stage II (moderate graft sclerosis) 
The fibrosis occupies 30–60% of the core surface. The exocrine atrophy affects the 
majority of the lobules in their periphery (irregular 
contours) and in their central areas (thin fibrous strands criss-cross between individual 
acin). 
- Stage III (severe graft sclerosis) 
The fibrotic areas predominate and occupy more than 60% of the core surface with only 
isolated areas of residual acinar tissue and/or 
islets present. 
6. Other histological diagnosis. Pathological changes not considered to be due acute 
and/or chronic rejection. e.g. CMV pancreatitis, 
PTLD, etc. 
 
ª Categories from 2 to 6 may be diagnosed concurrently and should be listed in the diagnosis in the 
order of their clinico-pathological significance. 
º See Table 2 for morphological definition of lesions. 
ºº If there are no donor-specific antibodies or these data are unknown, identification of histological 
features of antibody-mediated rejection may be diagnosed as ‘suspicious for acute antibody- mediated 
rejection’, particularly if there is graft dysfunction 
Table 4. Diagnostic categories Banff working grading schemaa/o (Drachenberg et al., 2008). 
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Table 5. Pathological changes “other” than rejection in pancreas needle biopsies 
(Drachenberg et al., 2008). 
www.intechopen.com
 Understanding the Complexities of Kidney Transplantation 134 
Neuropathy: Initially after transplantation (SPK) neuropathy improves with correction of 
uraemia. Several studies reported improvement in motor and sensory nerve functions; 
confirmed by improved nerve conduction velocity. Less clear is the impact on autonomic 
function (arrhythmia, postural hypotension, diabetic diarrhoea, gastroparesis, neurogenic 
bladder, impotence, etc). Some data suggest that patients improve even with these 
symptoms but it is difficult to quantify (Nusser et al., 1991). 
Cardio-vascular disease: Also, the positive impact of functioning pancreas graft on micro-
vascular disease and cardiac function is well documented. This involve improvement in  
ventricular ejection function, reversal of diastolic function, and improved endothelial 
function.  
Quality of Life: The main benefit of pancreas transplantation is the improved patients’ quality 
of life. Sureshkumar, in his study (Sureshkumar et al., 2006), used three quality of life 
questionnaires (Diabetes Quality of Life Questionnaire, Medical Outcomes Questionnaire 
and Quality of Well-being Questionnaire) to compare outcomes of diabetics after SPK with 
patients on the Waiting List. He reports that SPK groups showed better diabetes-related 
quality of life.  
Patient Survival: Results of SPK suggests that this group of patients do better over diabetics 
receiving cadaveric kidney  transplants but there are no survival benefits compared to LRD 
recipients. The same study concludes that pancreas transplantation is not only life 
enhancing but also a life saving procedure (Reddy et al., 2003). 
 
Patient with T1DM
Suitable candidate for SPK?
Evaluate for KT 
(LRD or CKD)
LRD available SPK
SPLKLRD + PAK
Algorithm of transplant alternatives in diabetics
YES
YES
YES
NO
NO
eGFR < 30 ml/min
NO
PTA
 
T1DM – type-1 diabetes mellitus, KT – kidney transplant, LRD - living related donor,  
CKD – cadaver kidney donor 
Fig. 15. Algorithm to choose the best transplant alternatives for diabetics. 
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11. Summary 
The outcomes following pancreas transplantation have significantly improved in the last 
decade. Careful patient selection, better organ procurement, refinements in surgical 
technique, new immunosuppressive drug regiments and better graft monitoring have all 
contributed to excellent outcomes. The available data provides strong evidence that 
pancreas transplantation not only improves diabetics’ quality of life but also improves their 
medical conditions and prolongs their life expectancy.  
Pancreas transplantation has become the option of choice to treat patients with type-1 
diabetes. Currently several alternatives for these patients are available. The best option 
should be selected after careful patient assessment and individually weight pros and cons of 
each alternative (Fig. 15).  
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